CA3159376A1 - Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof - Google Patents
Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereofInfo
- Publication number
- CA3159376A1 CA3159376A1 CA3159376A CA3159376A CA3159376A1 CA 3159376 A1 CA3159376 A1 CA 3159376A1 CA 3159376 A CA3159376 A CA 3159376A CA 3159376 A CA3159376 A CA 3159376A CA 3159376 A1 CA3159376 A1 CA 3159376A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- cycloalkyl
- heterocyclyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911147956 | 2019-11-21 | ||
| CN201911147956.3 | 2019-11-21 | ||
| CN202010837381.4 | 2020-08-19 | ||
| CN202010837381 | 2020-08-19 | ||
| PCT/CN2020/130326 WO2021098811A1 (zh) | 2019-11-21 | 2020-11-20 | 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3159376A1 true CA3159376A1 (en) | 2021-05-27 |
Family
ID=75981069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3159376A Pending CA3159376A1 (en) | 2019-11-21 | 2020-11-20 | Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12559488B2 (https=) |
| EP (1) | EP4063363A4 (https=) |
| JP (1) | JP7781059B2 (https=) |
| KR (1) | KR20220103987A (https=) |
| CN (5) | CN120004887A (https=) |
| AU (1) | AU2020386587A1 (https=) |
| BR (1) | BR112022008000A2 (https=) |
| CA (1) | CA3159376A1 (https=) |
| MX (1) | MX2022005985A (https=) |
| TW (1) | TW202128690A (https=) |
| WO (1) | WO2021098811A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112142744A (zh) | 2019-06-28 | 2020-12-29 | 上海瑛派药业有限公司 | 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用 |
| TW202220993A (zh) * | 2020-08-07 | 2022-06-01 | 香港商德琪研發有限公司 | Atr抑制劑及其用途 |
| WO2022135560A1 (en) * | 2020-12-25 | 2022-06-30 | Impact Therapeutics (Shanghai) , Inc | Substituted imidazo[1,5-b]pyridazine compounds as kinase inhibitors and use thereof |
| KR20240012471A (ko) | 2021-05-21 | 2024-01-29 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 피라졸로헤테로아릴계 유도체의 약학적으로 허용 가능한 염 및 이의 결정형 |
| WO2023109883A1 (zh) * | 2021-12-15 | 2023-06-22 | 上海翊石医药科技有限公司 | 一类芳杂环取代的化合物及其制备方法和用途 |
| WO2024109727A1 (zh) * | 2022-11-21 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | 一种吡唑并杂芳基类衍生物的可药用盐的结晶形式 |
| CN119143753B (zh) * | 2023-06-14 | 2026-01-02 | 石药集团中奇制药技术（石家庄）有限公司 | 一种杂环类抗肿瘤化合物的盐及其晶型 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2921576T3 (es) | 2008-12-19 | 2022-08-29 | Vertex Pharma | Compuestos útiles como inhibidores de la quinasa ATR |
| US20110053923A1 (en) * | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
| SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| CA2819373A1 (en) * | 2010-12-09 | 2012-06-14 | Amgen Inc. | Bicyclic compounds as pim inhibitors |
| ME03336B (me) | 2013-03-12 | 2019-10-20 | Vertex Pharma | Inhibitori dnk-pk |
| AR095443A1 (es) | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | Heterociclos condensados con acción sobre atr |
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| US20190000850A1 (en) | 2015-02-09 | 2019-01-03 | The Regents Of The University Of California | Combination cancer therapy |
| WO2017118734A1 (en) | 2016-01-08 | 2017-07-13 | The Institute Of Cancer Research: Royal Cancer Hospital | Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer |
| CA3011189C (en) | 2016-01-14 | 2024-02-20 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| US11730734B2 (en) | 2016-09-12 | 2023-08-22 | University Of Florida Research Foundation, Incorporated | Use of ATR and Chk1 inhibitor compounds |
| WO2018153970A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine |
| EP3679041B1 (en) | 2017-09-08 | 2022-07-06 | Newave Pharmaceutical Inc. | Substituted pyrrolopyridines as atr inhibitors |
| CN112654396B (zh) * | 2018-09-07 | 2025-07-01 | 默克专利股份公司 | 5-吗啉-4-基-吡唑并[4,3-b]吡啶衍生物 |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
-
2020
- 2020-11-20 TW TW109140787A patent/TW202128690A/zh unknown
- 2020-11-20 CN CN202510105110.2A patent/CN120004887A/zh active Pending
- 2020-11-20 BR BR112022008000A patent/BR112022008000A2/pt unknown
- 2020-11-20 AU AU2020386587A patent/AU2020386587A1/en active Pending
- 2020-11-20 JP JP2022529505A patent/JP7781059B2/ja active Active
- 2020-11-20 MX MX2022005985A patent/MX2022005985A/es unknown
- 2020-11-20 WO PCT/CN2020/130326 patent/WO2021098811A1/zh not_active Ceased
- 2020-11-20 CN CN202510104960.0A patent/CN120004872A/zh active Pending
- 2020-11-20 CN CN202080066108.4A patent/CN114423760B/zh active Active
- 2020-11-20 KR KR1020227019663A patent/KR20220103987A/ko not_active Ceased
- 2020-11-20 CN CN202510105174.2A patent/CN120004888A/zh active Pending
- 2020-11-20 US US17/778,632 patent/US12559488B2/en active Active
- 2020-11-20 EP EP20890856.6A patent/EP4063363A4/en active Pending
- 2020-11-20 CN CN202510105045.3A patent/CN120004886A/zh active Pending
- 2020-11-20 CA CA3159376A patent/CA3159376A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023502458A (ja) | 2023-01-24 |
| CN114423760A (zh) | 2022-04-29 |
| CN120004886A (zh) | 2025-05-16 |
| WO2021098811A1 (zh) | 2021-05-27 |
| KR20220103987A (ko) | 2022-07-25 |
| EP4063363A1 (en) | 2022-09-28 |
| TW202128690A (zh) | 2021-08-01 |
| AU2020386587A1 (en) | 2022-06-02 |
| BR112022008000A2 (pt) | 2022-07-12 |
| CN120004872A (zh) | 2025-05-16 |
| EP4063363A4 (en) | 2023-11-29 |
| JP7781059B2 (ja) | 2025-12-05 |
| CN120004888A (zh) | 2025-05-16 |
| US20230018728A1 (en) | 2023-01-19 |
| CN120004887A (zh) | 2025-05-16 |
| MX2022005985A (es) | 2022-06-17 |
| US12559488B2 (en) | 2026-02-24 |
| CN114423760B (zh) | 2024-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3159376A1 (en) | Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof | |
| EP3889153A1 (en) | Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof | |
| CA3172285A1 (en) | Fused imidazole derivatives, preparation method and medical use thereof | |
| CA3180615A1 (en) | Pyridine-pyrimidine derivative, preparation method therefor and pharmaceutical use thereof | |
| JP2024519188A (ja) | 含窒素複素環系化合物、その調製方法及びその医薬的応用 | |
| US20220073521A1 (en) | Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof | |
| CN113825757B (zh) | 取代的稠合双环类衍生物、其制备方法及其在医药上的应用 | |
| CA3134405A1 (en) | Thienoheterocyclic derivative, preparation method therefor and medical use thereof | |
| CN112996783A (zh) | 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| CN112574212B (zh) | 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 | |
| EP4067349A1 (en) | Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof | |
| CN115867552B (zh) | 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| CA3186193A1 (en) | Oxa-azaspiro derivative, and preparation method therefor and pharmaceutical use thereof | |
| CN113004303A (zh) | 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用 | |
| CN110964034B (zh) | 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用 | |
| RU2775229C1 (ru) | Производное пиримидина и пятичленного азотсодержащего гетероцикла, способ его получения и его медицинские применения | |
| CN111187277B (zh) | 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| HK40070277B (zh) | 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用 | |
| HK40070277A (en) | Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof | |
| WO2021143821A1 (zh) | 稠合杂芳基类衍生物、其制备方法及其在医药上的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241028 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241028 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241028 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241028 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241028 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250424 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251125 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260108 |